KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) EPS (Weighted Average and Diluted) (2016 - 2025)

Neogenomics' EPS (Weighted Average and Diluted) history spans 15 years, with the latest figure at -$0.07 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 41.67% year-over-year to -$0.07; the TTM value through Dec 2025 reached -$0.83, down 33.87%, while the annual FY2025 figure was -$0.84, 35.48% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.07 in Q4 2025 per NEO's latest filing, up from -$0.21 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.59 in Q2 2021 to a low of -$0.4 in Q1 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.17, with a median of -$0.19 recorded in 2021.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 1083.33% in 2021 against a maximum downside of 525.0% in 2021.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.35 in 2021, then surged by 48.57% to -$0.18 in 2022, then surged by 38.89% to -$0.11 in 2023, then decreased by 9.09% to -$0.12 in 2024, then soared by 41.67% to -$0.07 in 2025.
  • Per Business Quant, the three most recent readings for NEO's EPS (Weighted Average and Diluted) are -$0.07 (Q4 2025), -$0.21 (Q3 2025), and -$0.35 (Q2 2025).